Providhe
An open-label early access phase 3b study of Ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma
Description: This trial has only 1 arm of treatment. All patients will receive Ivosidenib. Patients must have previously received treatment for locally advanced or metastatic cholangiocarcinoma
Study Phase: Phase 3
Principal Investigator: Prof. Maeve Lowery
Further information